1. Japan Partnership
With proven experience in Taiwan market, we have built (or are to build) partnership with major channel partners and therapy partners across Asia, such as China, Japan and Macao. For instance, after a series of due diligence into our operating know-how, in January 2013, Vectorite signed a therapy treatment agreement with 2 Immune-cell therapy institutions based in Japan. We are currently also in conversation with multiple storage & therapy partners across Asia and patients in these regions could conduct cell banking and Immune-cell therapy via our platform or partnership channels.
2. Patent Applications
| |
Name / Description
|
Domain
|
Filing Date
|
Number
|
Public Number
|
Status
|
| 1 |
Animmunegenic composition comprising peptides derived from cytomegalovirus and the use thereof |
Int’l |
2009/06/26 |
PCT/CN2009/000718 |
WO 2010/148541 A1 |
Processing (US, Japan, EPC) |
| 2 |
Amethodtoproduce immune cells and induce immune effector cells |
Taiwan |
2009/07/17 |
098124187 |
201103558 |
2013/07 Approved |
| China |
2009/06/22 |
200910149433.2 |
CN101928695A |
2013/02/08 Approved |
| Int’l |
2011/10/31 |
PCT/CN/2011/001811 |
NA |
Processing |
|
